• Zura Bio’s third-quarter 2026 net loss widened 43% year over year to $25.83 million.
• Research and development expenses jumped 63% to $19.49 million, driven by Phase 2 tibulizumab programs and NEXUS-PMR start-up activities.
• Cash and cash equivalents totaled $187.7 million at September 30, supporting planned operations through at least the end of 2028.
• Tibulizumab topline results remain expected from TibuSHIELD in the fourth quarter of 2026 and TibuSURE in the first half of 2027.
• The Phase 2 NEXUS-PMR study remains scheduled to begin by year-end 2026 following FDA clearance to proceed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261027689094) on October 27, 2026, and is solely responsible for the information contained therein.